GlobalData on MSN
Aisa Pharma reports positive results for AISA-021
The study included 64 patients and was conducted in two segments.
Aisa Pharma, Inc., a clinical-stage biopharmaceutical company focused on therapies for systemic sclerosis, today announced results from its Phase 2 RECONNOITER trial of AISA-021 (cilnidipine), a novel ...
Aisa Pharma announces positive results from phase 2 RECONNOITER trial of cilnidipine in patients with systemic sclerosis-associated Raynaud's phenomenon: Boston Monday, March 9, 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results